Scholarlink

<p>Breast cancer is the second leading cancer type in women, accounting for 11.6% of all cancers. Recently, its incidence has increased in younger individuals. Estrogen receptors (ERs) play important roles in the development and progression of breast cancer by controlling hormone signaling. Therefore, targeting ERs is one of the most promising therapeutic strategies for treating ER-positive breast cancer. High heterogeneity contributes to the tumorigenicity, metastatic ability, and therapeutic resistance of breast cancer. However, drug discovery studies at the single-cell level are lacking. In the present study, we used single-cell sequencing data analysis, together with a network pharmacology approach, to determine the targets and molecular mechanisms of formononetin in ER-positive breast cancer. Comparative single-cell sequencing analysis identified 3899, 3395, 333, 398, 398, and 17 differentially expressed genes in stromal cells, epithelial cells, fibroblasts, neutrophils, eosinophils, and macrophages, respectively, of ER-positive breast cancer compared with normal breast tissues. Further network pharmacology analysis highlighted the importance of formononetin targets in biological functions and signaling pathways related to immune and inflammatory responses, metastatic ability, metabolism, cell proliferation, and gland development in different ER-positive breast cancer cell types. For the first time, we used a systems biology approach to investigate the targets of formononetin and its anti-ER-positive breast cancer mechanisms at the single-cell level.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Single cell sequencing and computational findings reveal anti-estrogen receptor-positive breast cancer roles of formononetin

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Bihui Li,
  • Shuangxi Li,
  • Ruihan Li,
  • Menzhen Li,
  • Zhaoquan Huang

摘要

Breast cancer is the second leading cancer type in women, accounting for 11.6% of all cancers. Recently, its incidence has increased in younger individuals. Estrogen receptors (ERs) play important roles in the development and progression of breast cancer by controlling hormone signaling. Therefore, targeting ERs is one of the most promising therapeutic strategies for treating ER-positive breast cancer. High heterogeneity contributes to the tumorigenicity, metastatic ability, and therapeutic resistance of breast cancer. However, drug discovery studies at the single-cell level are lacking. In the present study, we used single-cell sequencing data analysis, together with a network pharmacology approach, to determine the targets and molecular mechanisms of formononetin in ER-positive breast cancer. Comparative single-cell sequencing analysis identified 3899, 3395, 333, 398, 398, and 17 differentially expressed genes in stromal cells, epithelial cells, fibroblasts, neutrophils, eosinophils, and macrophages, respectively, of ER-positive breast cancer compared with normal breast tissues. Further network pharmacology analysis highlighted the importance of formononetin targets in biological functions and signaling pathways related to immune and inflammatory responses, metastatic ability, metabolism, cell proliferation, and gland development in different ER-positive breast cancer cell types. For the first time, we used a systems biology approach to investigate the targets of formononetin and its anti-ER-positive breast cancer mechanisms at the single-cell level.